A new study helps explain why certain cancers don't respond to treatment, and offers hope for overcoming this deadly resistance.
Reported by Science Daily 7 hours ago.
↧
Scientists discover a mechanism of drug resistance in breast and ovarian cancer
↧
Children who undergo CT scans may be at a higher risk of brain cancer
Researchers, led by Dr Michael Hauptmann at the Netherlands Cancer Institute, found rates of cancer were 1.5 times higher in the children who had underwent at least one CT scan in their life.
Reported by MailOnline 8 hours ago.
↧
↧
Scientists discover how cannabis triggers hunger so they can treat appetite loss
The researchers in Washington say the study is urgent since marijuana is given to cancer and HIV patients to treat appetite loss, but we do not know how it interacts with their bodies or their diseases.
Reported by MailOnline 8 hours ago.
↧
CBHI Presents Innovative Sigma Anti-Bonding Calcium (SAC) In Medical Industry
The first ionized calcium delivery system to body awakens body’s dormant response
FLUSHING, N.Y. (PRWEB) July 18, 2018
Calcium & Bone Health Institute (CBHI), partnering with Pronuvia, Inc., has initiated to introduce the revolutionary Sigma Anti-Bonding Calcium (SAC) to medical industry. Recently, the inventor of SAC calcium, Dr. Paul Lee, Ph.D. presented at series of well-known conferences, including Asia Pacific Dental Congress in front of 4,000 dentists (May 7-11) and International Anti-aging and Integrative Medicine (IAIM) International Conference (May 2-3). The presentation of the invention was well received by doctors as there has been no form of physiologically active ionized calcium which could be directly delivered to our bodies.
“While we are living in the world where the most abundant calcium intake is possible, a lot of people are still suffering from osteoporosis and more than 100 diseases derived from the deficiency of calcium,” said Dr. Lee, the president of CBHI. “That’s because most of calcium we take is absorbed as protein calcium which cannot be utilized in our body, causing kidney stone, heart attack, and stroke. I am very grateful to invent SAC calcium which is directly diffused into our body through stomach membrane without Vitamin D or digestion.”
Sigma Anti-bonding Calcium (SAC)
SAC calcium was invented by Dr. Paul Lee in 2009. The atomic orbitals of SAC calcium molecule have sigma anti-bonding and therefore, easily separated into atoms in the water. Any form of calcium from food or supplement comes into our body as inactive protein calcium which requires Vitamin D and peptide to be absorbed through active transport, without going to bone. On the other hand, SAC calcium is diffused into our blood vascular through passive transport. It is 200 times more soluble in water and has shown up to 80% bone mineral density increase in thousands of people. SAC calcium awakens body’s dormant response and the process is fully natural without side effect.
Benefit of Ionized calcium
Researches have shown that a lot of diseases are caused by the deficiency of calcium. Even though we have learned that physiologically active ionized calcium is key to treat many diseases, there has been no way to deliver the ionized calcium into our body. SAC calcium is the first ionized calcium delivery system into our body.
Tiny amount of ionized calcium triggers thyroid to release calcitonin which increases Ca2+ deposition in bones. It also activates excessive protein calcium in our body to ionized calcium. Therefore, SAC calcium works as a calcium activator of inactive calcium, a hormone regulator between thyroid and para thyroid hormone, and a calcium navigator to deposit into bone. Thousands of people experienced improvement of osteoporosis, arthritis, dental health, and severe chronic diseases such as cancer.
Many researches have explained how ionized calcium can give benefit to treat cancer. It restores apoptosis of cancer as P53 gene is freed from NF-Kb protein, prevents dysfunction of mitochondria and P53 mutation, and neutralizes lactic acid in cancer preventing proliferation of cancer.
Availability
SAC calcium products are available in USA and many other countries. Inquiries are available at http://www.pronuvia.com. The line of products includes MaraGen (good for cancer or incurable diseases), MegaGen (good for osteoporosis), CartiGen (good for joint), DentiGen (good for dental health) and Osso Jr. (good for kids).
About CBHI
Calcium and Bone Health Institute (CBHI) is Canada based research organization that has invented Sigma Anti-bonding Calcium (SAC). It has partnership with many universities and research organizations. Its invented SAC calcium was tried by thousands of people with great responses from their bodies. It continues to research on many degenerative challenging diseases such as cancer, stem cell, diabetes, Alzheimer’s disease and more.
About Pronuvia
Pronuvia markets SAC calcium products in US and worldwide. While many previous researches by other scholars are introduced and CBHI continues to do the research, Pronuvia does not claim any treatment or prevention of specific diseases. Pronuvia works with doctors and tries to help patients as supplements. It strives to provide better lives and hopes to many people.
Media Contact
info(at)pronuvia(dot)com Reported by PRWeb 6 hours ago.
FLUSHING, N.Y. (PRWEB) July 18, 2018
Calcium & Bone Health Institute (CBHI), partnering with Pronuvia, Inc., has initiated to introduce the revolutionary Sigma Anti-Bonding Calcium (SAC) to medical industry. Recently, the inventor of SAC calcium, Dr. Paul Lee, Ph.D. presented at series of well-known conferences, including Asia Pacific Dental Congress in front of 4,000 dentists (May 7-11) and International Anti-aging and Integrative Medicine (IAIM) International Conference (May 2-3). The presentation of the invention was well received by doctors as there has been no form of physiologically active ionized calcium which could be directly delivered to our bodies.
“While we are living in the world where the most abundant calcium intake is possible, a lot of people are still suffering from osteoporosis and more than 100 diseases derived from the deficiency of calcium,” said Dr. Lee, the president of CBHI. “That’s because most of calcium we take is absorbed as protein calcium which cannot be utilized in our body, causing kidney stone, heart attack, and stroke. I am very grateful to invent SAC calcium which is directly diffused into our body through stomach membrane without Vitamin D or digestion.”
Sigma Anti-bonding Calcium (SAC)
SAC calcium was invented by Dr. Paul Lee in 2009. The atomic orbitals of SAC calcium molecule have sigma anti-bonding and therefore, easily separated into atoms in the water. Any form of calcium from food or supplement comes into our body as inactive protein calcium which requires Vitamin D and peptide to be absorbed through active transport, without going to bone. On the other hand, SAC calcium is diffused into our blood vascular through passive transport. It is 200 times more soluble in water and has shown up to 80% bone mineral density increase in thousands of people. SAC calcium awakens body’s dormant response and the process is fully natural without side effect.
Benefit of Ionized calcium
Researches have shown that a lot of diseases are caused by the deficiency of calcium. Even though we have learned that physiologically active ionized calcium is key to treat many diseases, there has been no way to deliver the ionized calcium into our body. SAC calcium is the first ionized calcium delivery system into our body.
Tiny amount of ionized calcium triggers thyroid to release calcitonin which increases Ca2+ deposition in bones. It also activates excessive protein calcium in our body to ionized calcium. Therefore, SAC calcium works as a calcium activator of inactive calcium, a hormone regulator between thyroid and para thyroid hormone, and a calcium navigator to deposit into bone. Thousands of people experienced improvement of osteoporosis, arthritis, dental health, and severe chronic diseases such as cancer.
Many researches have explained how ionized calcium can give benefit to treat cancer. It restores apoptosis of cancer as P53 gene is freed from NF-Kb protein, prevents dysfunction of mitochondria and P53 mutation, and neutralizes lactic acid in cancer preventing proliferation of cancer.
Availability
SAC calcium products are available in USA and many other countries. Inquiries are available at http://www.pronuvia.com. The line of products includes MaraGen (good for cancer or incurable diseases), MegaGen (good for osteoporosis), CartiGen (good for joint), DentiGen (good for dental health) and Osso Jr. (good for kids).
About CBHI
Calcium and Bone Health Institute (CBHI) is Canada based research organization that has invented Sigma Anti-bonding Calcium (SAC). It has partnership with many universities and research organizations. Its invented SAC calcium was tried by thousands of people with great responses from their bodies. It continues to research on many degenerative challenging diseases such as cancer, stem cell, diabetes, Alzheimer’s disease and more.
About Pronuvia
Pronuvia markets SAC calcium products in US and worldwide. While many previous researches by other scholars are introduced and CBHI continues to do the research, Pronuvia does not claim any treatment or prevention of specific diseases. Pronuvia works with doctors and tries to help patients as supplements. It strives to provide better lives and hopes to many people.
Media Contact
info(at)pronuvia(dot)com Reported by PRWeb 6 hours ago.
↧
Scientists uncover DNA 'shield' w/crucial roles in normal cell division
New fundamental complex in cells drives 'messy' form of DNA repair. In immune cells, this is crucial to make antibodies. In cancer, mutations in complex could lead to resistance to BRCA-targeting PARP inhibitor drugs or platinum chemotherapies.
Reported by Science Daily 3 hours ago.
↧
↧
RNA molecules that regulate action of male hormone in prostate cancer identified
A study detected in tumoral tissue hundreds of RNAs that do not encode proteins but appear to regulate effects of androgens and androgen receptors on gene expression in tumors. By investigating the connection between the presence of these molecules and tumor aggressiveness, the research paves the way for new scientific approaches focusing on the transcription process of noncoding RNA.
Reported by Science Daily 2 hours ago.
↧
Oppenheimer expects launch of CTI BioPharma’s rare blood cancer treatment pacritinib to be delayed until 2022
An Oppenheimer analyst said Wednesday that she expected the launch of CTI BioPharma Corp’s (NASDAQ:CTIC) pacritinib, which holds great promise as a treatment for patients with advanced myelofibrosis, to be delayed until 2022. “Owing to the financial impact of the delayed estimated launch of pacritinib, we are lowering our target price to US$4 per share from our prior US$6,” Oppenheimer analyst Leah Rush Cann wrote in a note to analysts. According to the Mayo Clinic, myelofibrosis is a serious bone marrow disorder that disrupts the body's normal production of blood cells and causes a rare blood cancer. The news sent the Seattle, Washington biotech stock reeling 42.4% to US$2.30. “Our financial outlook for 2018-19 is basically unchanged. For 2020-24, our revenue forecast is being reduced by 55%, 88%, 86.2%, and 51.0%, respectively, to account for the delay for pacritinib,” wrote Oppenheimer analyst Leah Rush Cann in a note to analysts. Small-Cap Snapshot: Coherus BioSciences soars after addressing issues by the European regulator for its biosimilar application “The net effect is an increase in our estimated loss per share from US$0.75 to US$0.94 for 2020 and from US$0.12 to US$1.19 for 2021. We no longer estimate that CTI will be EPS-positive by 2024 and are lowering our EPS to loss per share forecasts,” she added. Key Points CTI BioPharma announced Wednesday that it recently conducted a Type B meeting with the US Food and Drug Administration (FDA) to discuss the regulatory pathway for pacritinib. “CTI reported that based on FDA feedback, it now plans to conduct a randomized phase III study in patients with myelofibrosis,” wrote Cann. “The dosing for the phase III study will be determined using the results of the PAC203 study. Management reiterated that PAC203 is expected to complete enrollment by the end of 2018, with full top-line data expected in the second quarter of 2019. The new phase III study is expected to open in 2019,” she added. READ: CTI BioPharma reports failure of Phase 3 non-Hodgkins lymphoma trial CTI Biopharma is currently evaluating pacritinib in two phase III development programs for the treatment of primary myelofibrosis and a phase II program for primary myelofibrosis previously treated with ruxolitinib. Investment thesis “Based on our expectation that CTI BioPharma will introduce its first product in the US in the next few years, we estimate that total revenue will grow to US$196.8mln in 2024,” wrote Cann. “If we discount our estimated revenue for risk-of-failure and for investment returns, we arrive at a 12 to18 month target price of US$4,” she added. Contact Uttara Choudhury at uttara@proactiveinvestors.com Follow her on Twitter: @UttaraProactive
Reported by Proactive Investors 6 hours ago.
↧
Cancer victim gets new tongue made from her leg
Cynthia Zamora, 57, from San Diego, California, was given a second chance at being able to speak when, after her tongue was removed due to cancer, a new one was fashioned from her thigh.
Reported by MailOnline 6 hours ago.
↧
World-first blood test detects skin cancer before it spreads to body
Scientists in Australia have developed a world-first blood test to detect skin cancer before it spreads through the body. The test could potentially allow early detection of melanoma, the most deadly form of skin cancer, and increase...
Reported by New Zealand Herald 3 hours ago.
↧
↧
US Senators Learn How Sharks Might Help Cure Cancer
Watch VideoIt might seem odd that U.S. senators just held a hearing about "innovations in shark research and technology." But when it comes to public health, sharks might have a lot to offer us humans.Experts told the Senate commerce committee sharks are an important lab animal, even if they are a little unorthodox. They say sharks' biology could teach us things we can't learn from lab monkeys or mice.
Sharks are one of the only animals with immune systems that can fight cancer with few or no side effects. Researchers say shark cells could help us understand cancer responses in humans — or someday even fight human cancer in clinical trials.
*SEE MORE: This Zebra Shark Shocked Researchers By Giving Birth Without A Male*
One witness also said shark jaws could be a good model for artificial joints. Shark jaws are made of cartilage, which relaxes when the animal opens its jaw but stiffens when it prepares to bite into something strong. If we could figure out exactly how sharks do that, we might be able to print stronger prostheses.
But to make medical advances like these, experts say they need more partnerships and more funding to find sharks in the first place. A government agency might be able to help there: Witnesses proposed using a network of NASA satellites to track sharks no matter where they went in the oceans. Reported by Newsy 4 hours ago.
↧
Take a Number: More Americans Are Dying of Cirrhosis and Liver Cancer
Death rates from both diseases have risen sharply, particularly among young adults over the last decade. A possible villain: the Great Recession.
Reported by NYTimes.com 3 hours ago.
↧
"Smurf" fights back against prostate cancer with charity head shave
He said its a way of giving something back
Reported by Western Morning News 2 hours ago.
↧
Daily Horoscope: Find out what the stars have in store for you — July 19, 2018
It's a new day, a new beginning. Its all about starting life afresh. So as you begin a new journey, find out what the stars have in store for you today. There are twelve zodiac signs and each has its distinct feature. Be it, Aries, Taurus, Gemini, Cancer, Leo, Virgo, Libra, Scorpio, Sagittarius, Capricorn, Aquarius and Pisces - each of the signs have something unique to tell.
Reported by Zee News 1 hour ago.
↧
↧
Cannabinoids May Have A Vast Array Of Anti-Cancer Effects
Previous research has shown that cannabinoids can help lessen side effects of anti-cancer therapies. Now a new British Journal of Pharmacology review has examined their potential for the direct treatment of cancer.
Phytocannabinoids are the most notable type of cannabinoid, and they occur naturally in the cannabis plant. Studies have shown that cannabinoids may stop cancer cells from dividing and invading normal tissue, and they may block the blood supply to tumors.
Some studies also indicate that cannabinoids may enhance the body’s immune response against the growth and spread of tumors.
“There is still a need for additional anti-cancer drugs. In this context accumulating data from preclinical models suggest that cannabinoids elicit anti-cancer effects on several levels of cancer progression,” said author Prof. Burkhard Hinz, of Rostock University Medical Center, in?Germany. “Clinical studies are now urgently needed to investigate the impact of cannabinoids on cancer growth and progression in patients.” Reported by Eurasia Review 1 hour ago.
Phytocannabinoids are the most notable type of cannabinoid, and they occur naturally in the cannabis plant. Studies have shown that cannabinoids may stop cancer cells from dividing and invading normal tissue, and they may block the blood supply to tumors.
Some studies also indicate that cannabinoids may enhance the body’s immune response against the growth and spread of tumors.
“There is still a need for additional anti-cancer drugs. In this context accumulating data from preclinical models suggest that cannabinoids elicit anti-cancer effects on several levels of cancer progression,” said author Prof. Burkhard Hinz, of Rostock University Medical Center, in?Germany. “Clinical studies are now urgently needed to investigate the impact of cannabinoids on cancer growth and progression in patients.” Reported by Eurasia Review 1 hour ago.
↧
RGCIRC Launches Drive to Raise Awareness about Sarcoma Cancer
“There is urgent need to raise awareness about *Sarcoma*, the cancer of Bone & Soft tissues, to save life and limbs of young who are falling prey to this cancer. There are about 250 types of Cancers out of which only few major ones are being talked about. But there are many for which we are not even aware of. One such Cancer is Sarcoma," says *Dr. Manish Pruthi, Consultant – Musculoskeletal Oncology,* *Rajiv Gandhi Cancer Institute and Research Centre*, Rohini and Niti Bagh.*Dr. Manish Pruthi*
A sarcoma is a rare kind of cancer. Sarcomas are different from the much more common carcinomas because they happen in a different kind of tissue. Sarcomas grow in connective tissue - cells that connect or support other kinds of tissue in your body. These tumors are most common in the bones, muscles, tendons, cartilage, nerves, and blood vessels of your arms and legs, but they can also happen in other areas of your body.
Though the sarcomas accounts for 3% of all cancers in adults and 10 – 15% in pediatric age group, the disease needs to be considered in right earnest to save life as well as limbs.
The impact is significant because a child developing a cancer and that too in a limb and sometime requiring amputation or big surgeries and then getting restricted for whole life is significant.
“There is a need of awareness as the cases are being reported late and there's risk of losing limb in young children. Another reason for lack of awareness is that there are not many surgeons who are doing Sarcoma Surgeries," says *Dr. Pruthi*.
Usually the tumor gets un-noticed in limbs or an inappropriate surgery is done. In such case this leads to damage and major risk of losing the limb is there, which affects the life of young children / adults. We need to preserve the function and cure the cancer.
Sarcoma happens in young age and at that age there are no major risk factors like chewing tobacco or poor lifestyle. So initially when it happens, most parents are naturally in shock. In NCR, a major issue is that not many hospitals have Sarcoma management teams.
Talking about prevention, *Dr. Pruthi* says, “Prevention doesn't play a role here, as there is no risk factor, what's important is early diagnosis. One should not ignore the persistent pain or increasing swelling in limbs, which is not responding to conservative treatment. Recently we treated a patient from Canada for Sarcoma, but he also remained poorly diagnosed for nearly two months."
It's not that every tumor / lump is cancerous, it could be an infection or a benign tumor. Sarcoma is a rare condition to have. Emphasis should be on not ignoring increasing swelling or pain in limbs especially in young adults, as it could be Sarcoma. Be aware, create awareness, diagnose Sarcoma early, Dr. Pruthi winds up. Reported by NewsVoir 8 minutes ago.
↧
After Three Back-to-Back Trials, Tobacco Companies Forced to Pay Millions to Families
*FORT LAUDERDALE, FL / ACCESSWIRE / July 19, 2018 / *After months of three back-to-back cases against big tobacco, Schlesinger Law Offices, P.A. has secured victories for three families who lost loved ones to smoking. The legal marathon began back in May with the Schlesinger team working relentlessly for two months, putting in thousands of hours of work to get the best possible outcome for their clients.It started in Broward County, Florida, last month, when a jury awarded $20 million in damages against R.J. Reynolds Tobacco Company and Philip Morris USA Inc., for both the pain and suffering of a deceased long-time cigarette smoker and her widower husband. The award included $8 million for the husband's pain and suffering, and a combined $12 million in punitive damages against the two tobacco companies.
Marion "Betty" Landi was 60 when she died in 1999, leaving behind her husband, Herbert, four children, and seven grandchildren - and the 1.5-pack-a-day cigarette addiction that took her life.
"The Landi's story is heart wrenching, but not unique. People start smoking as kids and become addicted. They trust marketing from the tobacco companies that cigarettes are safe, and eventually suffer a horrible death and unbearable personal loss," said Scott Schlesinger, who along with attorneys Brittany Chambers, Jonathan Gdanski and Steven Hammer with Schlesinger Law Offices, represented these families. "Juries are seeing through the deception and finally holding tobacco companies accountable for their lies."
Weeks later, jurors in Palm Beach County imposed a $500,000 punitive verdict against R.J Reynolds to the widow of Nick Perrotto. Perrotto smoked for 40 years before being diagnosed with lung cancer in 1992. He died a few years later at the early age 57. In 2014, Deborah Perrotto was awarded more than $4 million dollars in compensatory damages.
In another example, this week a jury awarded $5 million dollars in punitive damages to Myron Kaplan, for his late wife's death. Sheila Kaplan smoked a variety of cigarette brands manufactured and marketed by the defendants, including Camel, Marlboro and Parliament. She was diagnosed with lung cancer in 1994 and later succumbed from her involvement with the brands.Sheila Kaplan in 1959
"We are on a mission here, with no plans to slow down anytime soon. These back-to-back wins send a major message to big tobacco," said Schlesinger. "It was an impressive run that gives us hope more families will get the justice they deserve in the future."
The Landi, Perrotto and Kaplan cases are among thousands of similar "Engle Progeny" cases stemming from the Florida Supreme Court overturning a $145 billion verdict against the companies. The court also ruled plaintiffs - numbering close to 700,000 - could use findings from that case to file future lawsuits against tobacco companies.
Schlesinger Law is lead counsel in the national multi-district litigation against Reynolds Natural American Spirit cigarette, which is pending in the federal district court in New Mexico. The lawsuit was brought under the False and Deceptive Unfair Trade Practices Act. Now, other firms and plaintiffs around the country have joined to stop the spread of "organic natural" cigarettes.
*ABOUT SCHLESINGER LAW OFFICES*
Based in Fort Lauderdale, Florida, Schlesinger Law Offices is a personal injury law firm dedicated to holding corporations, manufacturers and medical providers accountable for harm caused to members of the public by acts of negligence and misconduct. The firm has a reputation for powerful advocacy and has obtained justice and compensation for hundreds of clients. For more information, log on to www.schlesingerlawoffices.com or call (954) 866-5493.
For media inquires contact Lauren Berger lberger@BoardroomPr.com
*SOURCE:* Scheslinger Law Offices PA Reported by Accesswire 2 hours ago.
↧
Cancer patients who use alternative medicine have higher risk of death
The Yale team warns the findings should be a red flag to doctors and patients as the powerful - but under-researched - industries of supplements, vitamins and cannabis gain traction.
Reported by MailOnline 6 hours ago.
↧
↧
Gap between dinner and bedtime linked to lower cancer risk: study
New research has found that eating your evening meal at least two hours before going to bed is linked with a lower risk of breast and prostate cancer.
Reported by CTV News 5 hours ago.
↧
Mersana Therapeutics shares plummet after FDA puts partial hold on key cancer drug trial
Shares in Mersana Therapeutics (NASDAQ:MRSN) plunged Thursday after the biopharma group reported that the US Food and Drug Administration has partially halted a Phase 1 study evaluating its key cancer drug in the wake of a patient’s death. No new patients will be enrolled in the early-stage study of XMT-1522, but current participants will be able to continue to receive the drug, according to Mersana. The FDA opted to block new participants from joining the Phase 1 trial after Mersana reported the death of a patient who took part in it. News of the FDA’s partial clinical hold on the trial left Mersana shares reeling by 39% to US$10.09. Analyst unfazed But the announcement didn't rattle Michael Ulz, a senior research analyst with Baird Equity Research, who is keeping his Outperform rating and a US$30 price target on the stock. While Ulz is more cautious on XMT-1522 due to the uncertainty related to the partial hold, he stressed that it remains “unclear if the event was drug-related.” “[As] such, we await further clarity,” he said. FDA review Mersana is working with the FDA’s investigators to review the event and attempt to resolve the clinical hold. “Based on the totality of the data we have for XMT-1522, we believe that it continues to be a promising drug candidate in the solid tumor setting and we will be initiating the proper steps with the objective of resuming enrollment,” said Anna Protopapas, CEO of Mersana, in a statement. The Phase 1 study is evaluating XMT-1522 in patients with HER2-expressing tumors who are battling breast, lung and stomach cancers. The partial clinical hold does not affect the early stage Phase 1 trial of Mersana’s other cancer drug candidate XMT-1536, which fights cancerous tumors expressing NaPi2b. Contact Ellen Kelleher at ellen@proactiveinvestors.com
Reported by Proactive Investors 6 hours ago.
↧
19th-century Italian teen to be canonized during youth Synod
Vatican City, Jul 19, 2018 / 10:01 am (CNA/EWTN News).- Bl. Nunzio Sulprizio, who died at the age of 19 from bone cancer, will be declared a saint Oct. 14 during the Synod of Bishops on young people, faith, and vocational discernment, Pope Francis announced Thursday.
The pope announced the date of the young Italian’s canonization during an ordinary public consistory at the Vatican July 19. The canonization will take place alongside six others, including that of Bl. Oscar Romero and Bl. Pope Paul VI, who presided over Sulprizio’s beatification.
At the beatification Dec. 1, 1963, Paul VI said that Bl. Nunzio Sulprizio teaches us that “the period of youth should not be considered the age of free passions, of inevitable falls, of invincible crises, of decadent pessimism, of harmful selfishness. Rather, he will tell you how being young is a grace…”
“He will tell you that no other age than yours, young people, is as suitable for great ideals, for generous heroism, for the coherent demands of thought and action,” the pope continued. “He will teach you how you, young people, can regenerate the world in which Providence has called you to live, and how it is up to you first to consecrate yourselves for the salvation of a society that needs strong and fearless souls.”
Sulprizio said it was “God’s Providence” that cared for him during his short life, and would say, “Jesus endured so much for us and by his merits eternal life awaits us. If we suffer a little bit, we will taste the joy of paradise” and “Jesus suffered a lot for me. Why should I not suffer for him?”
Born in the Italian region of Abruzzo in 1817, Sulprizio learned the faith from a priest at the local school he attended and from his maternal grandmother.
He was orphaned before the age of six, and after the death of his grandmother three years later, went to live with an uncle, who took him on as an apprentice blacksmith, not permitting him to attend school anymore.
His uncle also mistreated him, sending him on long errands, beating him, and withholding meals if he thought things were not done correctly or the boy needed discipline. The young Sulprizio would take consolation in Eucharistic adoration and in praying the rosary.
While still very young, he contracted an infection in one of his legs, causing intense and constant pain, with a puss-oozing sore. Due to a lack of proper medical care, the boy developed gangrene, and was sent to a hospital in Naples. There he would unite his pain with Christ’s suffering on the cross, also helping his fellow patients.
During this time, Sulprizio was introduced to a colonel who treated him like a son and helped pay for his medical treatments. While in the hospital, the young man was visited by a priest who prepared him for his first confession and Holy Communion.
He also met St. Gaetano Errico, an Italian priest and founder of the Missionaries of the Sacred Hearts of Jesus and Mary, who promised him he could enter the religious order when he was old enough.
Though he experienced periods of increasing health, Sulprizio contracted bone cancer. His leg was amputated, but it did not help, and he died from the illness shortly after his 19th birthday in 1836. One of the last things he told his friend, the colonel, was, “be cheerful. From heaven I will always be helping you.”
Besides Bl. Pope Paul VI and Bl. Oscar Romero, the other canonizations to take place Oct. 14 are Bl. Francesco Spinelli, a diocesan priest and founder of the Institute of the Adorers of the Blessed Sacrament; Bl. Vincenzo Romano, a diocesan priest from Torre de Greco in Italy; Bl. Maria Caterina Kasper, a German nun and founder of the Institute of the Poor Handmaids of Jesus Christ; and Nazaria Ignazia of Saint Teresa of Jesus, founder of the Congregation of the Misioneras Cruzadas de la Iglesia Sisters.
The 2018 Synod of Bishops, a gathering of bishops from around the world, will take place Oct. 3-28 in Rome on the topic of young people, the faith and vocational discernment. Reported by CNA 6 hours ago.
The pope announced the date of the young Italian’s canonization during an ordinary public consistory at the Vatican July 19. The canonization will take place alongside six others, including that of Bl. Oscar Romero and Bl. Pope Paul VI, who presided over Sulprizio’s beatification.
At the beatification Dec. 1, 1963, Paul VI said that Bl. Nunzio Sulprizio teaches us that “the period of youth should not be considered the age of free passions, of inevitable falls, of invincible crises, of decadent pessimism, of harmful selfishness. Rather, he will tell you how being young is a grace…”
“He will tell you that no other age than yours, young people, is as suitable for great ideals, for generous heroism, for the coherent demands of thought and action,” the pope continued. “He will teach you how you, young people, can regenerate the world in which Providence has called you to live, and how it is up to you first to consecrate yourselves for the salvation of a society that needs strong and fearless souls.”
Sulprizio said it was “God’s Providence” that cared for him during his short life, and would say, “Jesus endured so much for us and by his merits eternal life awaits us. If we suffer a little bit, we will taste the joy of paradise” and “Jesus suffered a lot for me. Why should I not suffer for him?”
Born in the Italian region of Abruzzo in 1817, Sulprizio learned the faith from a priest at the local school he attended and from his maternal grandmother.
He was orphaned before the age of six, and after the death of his grandmother three years later, went to live with an uncle, who took him on as an apprentice blacksmith, not permitting him to attend school anymore.
His uncle also mistreated him, sending him on long errands, beating him, and withholding meals if he thought things were not done correctly or the boy needed discipline. The young Sulprizio would take consolation in Eucharistic adoration and in praying the rosary.
While still very young, he contracted an infection in one of his legs, causing intense and constant pain, with a puss-oozing sore. Due to a lack of proper medical care, the boy developed gangrene, and was sent to a hospital in Naples. There he would unite his pain with Christ’s suffering on the cross, also helping his fellow patients.
During this time, Sulprizio was introduced to a colonel who treated him like a son and helped pay for his medical treatments. While in the hospital, the young man was visited by a priest who prepared him for his first confession and Holy Communion.
He also met St. Gaetano Errico, an Italian priest and founder of the Missionaries of the Sacred Hearts of Jesus and Mary, who promised him he could enter the religious order when he was old enough.
Though he experienced periods of increasing health, Sulprizio contracted bone cancer. His leg was amputated, but it did not help, and he died from the illness shortly after his 19th birthday in 1836. One of the last things he told his friend, the colonel, was, “be cheerful. From heaven I will always be helping you.”
Besides Bl. Pope Paul VI and Bl. Oscar Romero, the other canonizations to take place Oct. 14 are Bl. Francesco Spinelli, a diocesan priest and founder of the Institute of the Adorers of the Blessed Sacrament; Bl. Vincenzo Romano, a diocesan priest from Torre de Greco in Italy; Bl. Maria Caterina Kasper, a German nun and founder of the Institute of the Poor Handmaids of Jesus Christ; and Nazaria Ignazia of Saint Teresa of Jesus, founder of the Congregation of the Misioneras Cruzadas de la Iglesia Sisters.
The 2018 Synod of Bishops, a gathering of bishops from around the world, will take place Oct. 3-28 in Rome on the topic of young people, the faith and vocational discernment. Reported by CNA 6 hours ago.
↧